<DOC>
	<DOCNO>NCT02460081</DOCNO>
	<brief_summary>Study PDA-002-DFU-003 Phase 2 , multicenter , randomize , double blind , placebo-controlled , dose range find study subject diabetic foot ulcer ( DFU ) peripheral arterial disease ( PAD ) . The study enroll approximately 24 subject . This study investigate hemodynamic effect , clinical efficacy , safety 3 monthly intramuscular ( IM ) injection PDA-002 subject DFU PAD .</brief_summary>
	<brief_title>Safety , Hemodynamic Effects Efficacy Intramuscular PDA-002 Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Males female , least 18 year age old time signing informed consent document . 2 . Diabetes mellitus Type 1 Type 2 . 3 . Diabetic foot ulcer severity Grade 1 ( full thickness ) Grade 2 Wagner Grading Scale great one month duration adequately respond conventional ulcer therapy . 4 . Subjects meet one follow criterion arterial insufficiency foot index ulcer : 1 . Peripheral arterial disease ABI ≥ 0.40 ≤ 0.80 TBI ≥0.30 ≤ 0.65 . 2 . Transcutaneous oxygen measurement 20 40 mmHg . 5 . No planned revascularization amputation next 3 month screen visit , opinion investigator . 6 . Dosing begin least 14 day fail reperfusion intervention least 30 day successful reperfusion intervention 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study , discretion investigator . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk participate study , discretion investigator . 3 . Pregnant lactating female . 4 . Subjects body mass index &gt; 40 mg/m2 Screening . 5 . Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 Screening calculate use Modification Diet Renal Disease Study equation history eGFR decline &gt; 15 mL/min/1.73 m2 past year . 6 . Untreated chronic infection treatment infection systemic antibiotic , include ulcer site . Subject must antibiotic free within 1 week prior dose Investigational Product ( IP ) . 7 . Known osteomyelitis infection cellulitis adjacent index ulcer . 8 . Limb pain rest due limb ischemia . 9 . Uncontrolled hypertension ( define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 180 mmHg Screening 2 independent measurement take subject sit rest least 5 minute ) . 10 . Poorly control diabetes mellitus ( hemoglobin A1c &gt; 12 % screen serum glucose ≥ 300 mg/dL ) . 11 . Untreated proliferative retinopathy . 12 . History malignant ventricular arrhythmia , Canadian Cardiovascular Society ( CCS ) Class IIIIV angina pectoris , myocardial infarction/PCI ( percutaneous coronary intervention ) /CABG ( coronary artery bypass graft ) precede 6 month prior sign Informed Consent ( ICF ) , pending coronary revascularization follow 3 month , transient ischemic attack/cerebrovascular accident precede 6 month , prior sign ICF and/or New York Heart Association [ NYHA ] Stage III IV congestive heart failure . 13 . Abnormal ECG : new right bundle branch block ( BBB ) ≥ 120 msec precede 3 month prior sign ICF . 14 . Uncontrolled hypercoagulation syndrome . 15 . Life expectancy le 2 year due concomitant illness . 16 . In opinion investigator , subject unsuitable cellular therapy . 17 . History malignancy within 5 year prior sign ICF except basal cell squamous cell carcinoma skin remote history cancer consider cure positive Pap smear subsequent negative followup . 18 . History hypersensitivity component product formulation ( include bovine porcine product , dextran 40 , dimethyl sulfoxide [ DMSO ] ) . 19 . Subject receive investigational agent —an agent device approve US Food Drug Administration ( FDA ) market use indication— within 90 day ( 5 halflives , whichever long ) prior treatment study therapy plan participation another therapeutic study prior completion study . 20 . Subject receive previous investigational gene cell therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PDA-002</keyword>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Randomized</keyword>
</DOC>